
Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc.(CLRB)股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
clrb · 股价预测 · 8 位分析师(近3月)· FMP · 更新于 2026年6月8日
分析师评级与共识
基于过去 3 个月内 8 位华尔街分析师
Buy
8 位分析师
共识
评级分布
12 个月目标价
High
$11.00
Consensus
$11.00
+338.2% upside
Low
$11.00
Median: $11 · Last Close: $2.51
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
短期股价预测
Low Activity算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $2.38 | ↓ 5.00% |
1-day model range: $2.33–$2.44. Peak: $2.44 (-5.00%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -50.0% |
| 2028 | — | -62.5% |
| 2029 | — | -67.2% |
| 2030 | — | -69.2% |
| 2031 | — | -70.2% |
基于技术分析的股价预测
14 项技术面信号(SMA×6 + EMA×6 + RSI + MACD)· EEAT 方法论透明
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · CLRB · Jun 8, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-10 | Maxim Group | Upgrade ↑ | Hold→Buy |
| 2025-05-14 | Maxim Group | Downgrade ↓ | Buy→Hold |
| 2024-12-11 | Oppenheimer | Downgrade ↓ | Outperform→Perform |
| 2024-11-19 | Oppenheimer | Maintains | Outperform→Outperform |
| 2024-03-28 | Roth MKM | Maintains | Buy→Buy |
| 2024-03-28 | Oppenheimer | Maintains | Outperform→Outperform |
| 2024-03-04 | Roth MKM | Maintains | Buy→Buy |
| 2022-11-04 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2020-11-25 | Maxim Group | Maintains | Buy→Buy |
| 2020-11-25 | Oppenheimer | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Cellectar Biosciences, Inc. (CLRB) stock. Of the recent 18 rating actions, 1 were upgrades and 2 were downgrades. 8 analysts currently cover CLRB.
分析师推荐趋势
CLRB analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
财务预测:EPS 与营收一致预期
Revenue This Year
$4M
↓ 91.8% YoY
Revenue Next Year
$7M
↑ 78.0% YoY
EPS This Year
$-2.05
EPS Next Year
$-1.60
↓ 21.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast CLRB EPS of $-2.05 for the current fiscal year, based on estimates from 2 analysts. The CLRB revenue forecast is $4M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
CLRB 股价预测由两类独立数据源支撑:来自 8 位华尔街分析师(S&P Global / FMP)的共识评级,以及基于历史日终价计算的技术分析。CLRB 的共识目标价为 $11.00(+338.2% 上行空间),分析师共识为 Buy。
CLRB 的短期预测(明日)为 $2.38(-5.00%)。 CLRB 对 2030 年的预测区间为 $1–$1。
Cellectar Biosciences, Inc. 在 NASDAQ 上市,代码 CLRB。CLRB 在 2027 年的整体展望偏积极,在覆盖分析师中约 88% 对应 Buy 共识。
常见问题
CLRB 预测 · 8 个问题根据 8 位华尔街分析师,CLRB 的 12 个月平均目标价为 $11.00,最高 $11.00、最低 $11.00。若有图表,中位目标价可在上方查看。相对当前价 $2.51,隐含约 +338.2% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.